Immunoglobulin Market: Global Traction steer Focus on R&D

The increase in the geriatric population and the prevalence of immunodeficiency diseases and auto-immune disorders are skyrocketing the popularity of immunoglobulin drugs. As a result, the global immunoglobulin market is expected to surge at a CAGR of 6.77% during the forecast period 2022-2028.

Research stated that more than 6 million people across the globe are affected by primary immunodeficiency diseases, and 70-90% of these remain undiagnosed. Further, 2020 witnessed the phase two clinical trial by Green Cross Corporation to evaluate the safety and effectiveness of Hyper-Ig GC5131 in patients with COVID-19 infection. Hence, several operating players are focusing on developing new immunoglobulin drugs, boosting the immunoglobulin market.

The intravenous immunoglobulin drugs are continually gaining popularity among patients to treat organ-specific diseases relating to the skin and the nervous system. Further, the United States Food and Drug Administration approves products, including intravenous immunoglobulin. For instance, approval of the supplemental Biologics License Application for PANZYGA of Pfizer Inc. for treating patients with rare neurological diseases of peripheral nerves.

The high cost of immunoglobulin therapy and the high risk of side effects can limit its adoption across the globe and hamper the overall market growth.

Market Expansion supported by Regional Trends

Based on the global scenario, the immunoglobulin market is studied in several developed and developing countries. The trending regions in the studied market are North America and Asia-Pacific.

Asia-Pacific to witness the fastest growth with a CAGR of 7.11%

The Asia-Pacific immunoglobulin market was valued at $2.9 billion in 2021 and is expected to reach $4.7 billion by 2028. The growth is expected due to factors like the rapid rise in the geriatric population, the prevalence of different diseases, and research and development across the region.

In China, the Health Minister of Yunnan Province has planned to establish around 24 plasma collection stations around the province. Further, there are increasing mergers and acquisitions among blood product companies across the country. For instance, Southern Shuanglin Bio-Pharmacy merged with Harbin Pacific Biopharmaceutical to restructure itself and raise money.

North America dominates with revenue of $9.8 billion by 2028

The North America immunoglobulin market is growing at a CAGR of 6.85% during the forecast period. With companies like CSL Behring, Pfizer Inc, ADMA Biologics etc., the regional market is expected to create innovation with technological advancement and product development. Furthermore, the increasing FDA approvals and increasing use of immunoglobulin products for ailing chronic diseases are further expected to strengthen the market during the forecasted period.

Trending Segmentation Prospects

The immunoglobulin market is segmented based on application, end-user, type, delivery mode and sales channel. Some of the trending categories in each segment are as follows:

• Immunoglobulin A (IgA) is expected to be the fastest growing type, with a CAGR of 6.60% during the forecast period.
• Subcutaneous is expected to grow at a CAGR of 7.34% while being the fastest delivery mode during the forecast period.
• Myasthenia Gravis is expected to be the fastest growing application, with a CAGR of 7.96% during the forecasting period.
• Hospitals & Clinics are expected to be the fastest growing end users with a CAGR of 6.47% during the forecast period.

Strategic Initiatives by Market Players

The top players in the market include Argenx SE, Pfizer, Cipla, and ADMA Biologics, Inc. There is cut-throat competition among the competitors owing to the growing R&D in the immunoglobulin market. In this regard, the following product launches by the operating players have influenced the market’s growth:

• Argenx SE confirmed that Japan's Ministry of Health, Labor, and Welfare certified its product, VYVGART, an intravenous infusion to treat patients who do not respond adequately to steroids or non-steroidal immunosuppressive treatments.
• Pfizer PANZYGA clearance by US FDA, an intravenous immunoglobulin to treat adult patients with chronic inflammatory demyelinating polyneuropathy.
• Cipla launched Roche's Covid antibody cocktail in India for treatment of the mild to moderate COVID-19 in adults and pediatric patients.

Concluding Statement

The immunoglobulin market’s growth is rapid due to the prevalence of various chronic illnesses, R&D by industry experts and the rising geriatric population. According to the National Clinical Trials (NCT) Registry, around 50 immunoglobulin-based clinical trials have been conducted in the United States in various stages of development.

Moreover, increasing application in medical specialties like neurology, immunology, dermatology, etc. have increased end-users’ focus on adopting immunoglobulin products for the treatment of a variety of illnesses and disorders. These significant technological breakthroughs in immunoglobulin drugs are taking the market to new heights.

FAQ 

Q1) What is the growth of the immunoglobulin market in terms of revenue?

The global immunoglobulin market was valued at $ 13616.82 million in 2021 and is expected to reach $21497.75 billion by 2028.

Q2) What is immunoglobulin helpful for?

Immunoglobulin is antibodies that help in fighting infections and diseases of the immune system.